Bio:

Katharina Blankart is an assistant professor in empirical health economics at the Faculty of Business Administration and Economics of University of Duisburg-Essen, a full member of  the health economics research center CINCH and head of the junior research group “Empirical Analysis of Health Care Markets (EACH)”. Blankart‘s research covers innovation management, regulatory science and analysis of health care system performance. Her research projects address market access and diffusion of health technologies, valued-based decision-making by health systems and providers, and the impacts of cost-efficiency measures on utilization. She is particularly interested in studying pharmaceutical markets and ambulatory care settings. Her projects use econometric methods that are informed by administrative data, document analyses and surveys. She is the recipient of the 2013 research award of the Society for Health Policy and Law to study health care systems.

Katharina Blankart received her degrees in economics and business research from Ludwig-Maximilians-Universität München (LMU). She holds a PhD in business administration with a focus on health economics from (LMU). She was head of the junior research group on pharmacoeconomics at Hamburg Center for Health Economics (HCHE), University of Hamburg between 2012 and 2016. In 2015/2016, she collaborated with Columbia Business School, New York, USA as visiting researcher.

Curriculum Vitae:

Professional experience

since 11/2022

Member of the Young Faculty Ruhr Graduate School in Economics, UA Ruhr

since 09/16

Assistant professor in empirical health economics,

Faculty of Business Administration and Economics, University of Duisburg-Essen, Essen, Germany

09/15 – 08/16

Visiting officer of Research,

Columbia Business School, Columbia University in the City of New York (USA)

05/12 – 08/16

Research associate at the Hamburg Center for Health Economics (HCHE),

Universität Hamburg, Hamburg, Germany

Head of the junior research group Pharmacoeconomics

07/08–04/12

Research fellow, Institute of Health Economics and Health Care Management, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany

Member of the working group Translational Health Economics

Education

05/2012

Completion of dissertation (Dr. oec. publ.) at Ludwig-Maximilians-Universität München, Germany

2009–2011

Post gradual studies, Master of Business Research, Ludwig-Maximilians-Universität München, Germany

2003-2008

Economics, Ludwig-Maximilians-Universität München, Germany

Honours and Awards:

• 17th Research Award of the Society for Health Policy and Law 2013, Munich

Fields of Research:

• Market access and diffusion of innovations
• Competition and agent behaviour in regulated health care markets
• Management of technologies and health
• Quantitative methods

Publications:

• Blankart, Katharina E.; Lichtenberg, Frank R.: The Effects of Off-label Drugs Use on Disability and Medical Expenditure, Research, National Bureau Of Economic (Ed.), 2022. Full textCitationDetails
• Benjamin Birkner MSc, Katharina E. Blankart PhD: The Effect of Biosimilar Prescription Targets for Erythorpoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany. In: Value in Health, Vol 25 (2022) No 9, p. 1528-1538. Full textCitationDetails
• Blankart, Katharina; Naci, Huseyin; Chandra, Amitabh: Availability of New Medicines in the US and Germany From 2004 to 2018. In: JAMA Network Open, Vol 5 (2022) No 8. Full textCitationDetails
• Katharina E. Blankart PhD, Stefan Felder PhD: Do Medicine Shortages Reduce Access and Increase Pharmaceutical Expenditure? A Retrospective Analysis of Switzerland 2015-2020. In: Value in Health, Vol 25 (2022) No 7, p. 1124-1132. Full textCitationDetails
• Vadia R, Blankart KE.: Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe - A knowledge production function of cardiovascular research and funding in Europe. In: Region (2021) No 8(2), p. 57-81. doi:10.18335/region.v8i2.352CitationDetails
• Avdic D, Blankart KE: Do soft cost-control measures change productivity? - Preferred statin prescribing in Germany, 2021. doi:https://doi.org/10.5465/AMBPP.2021.226) CitationDetails
• K E, Blankart; F R, Lichtenberg: Are patients more adherent to newer drugs?. In: Health Care Management Science, Vol 2020 (2020). doi:https://doi.org/10.1007/s10729-020-09513-5CitationDetails
• K E, Blankart; T, Stargardt: The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. In: Health Economics, Vol 2020 (2020). Full textCitationDetails
• K E, Blankart; F, Arndt: Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. In: International Journal of Environmental Research and Public Health, Vol 2020 (2020) No 17. doi:https://doi.org/10.3390/ijerph17114113CitationDetails
• V, Winter; M K, Thomsen; J, Schreyögg; K E, Blankart; L, Duminy; L, Schoeneberger; J P, Ansah; D, Matchar; C R, Blankart; E, Oppel; U T, Jensen: Improving Service Provision - The Health Care Services’ Perspective. In: Journal of Service Management Research (2019) No 3(4), p. 163-183. Full textCitationDetails
• M S, Kurte; K E, Blankart: Ambulant-sensitive Krankenhausfälle in Deutschland – Abgrenzung, Prävalenz und Kosten. In: Gesundheitsökonomie & Qualitätsmanagement, Vol 2019 (2019). doi:10.1055/a-0890-9600Full textCitationDetails
• D, Guhl; K E, Blankart; T, Stargardt: Service quality and perceived customer value in community pharmacies. In: Health Services Management Research (2019) No 32(1), p. 36-48. doi:10.1177/0951484818761730Full textCitationDetails
• V D, Lauenroth; K E, Blankart; T, Stargardt: Stakeholder Participation in Regulatory Decision-Making, 11748. Proceedings, Academy Of Management (Ed.), 2018. Full textCitationDetails
• K E, Fischer; T, Koch; K, Kostev; T, Stargardt: The impact of physician-level drug budgets on prescribing behaviour. In: European Journal of Health Economics, Vol 19 (2017) No 2, p. 213-222. doi:10.1007/s10198-017-0875-9Full textCitationDetails
• K E, Fischer; K, Peters; T, Stargardt: Information on product quality, change agency and product adoption, 13580. Proceedings, Academy Of Management (Ed.), 2017. Full textCitationDetails
• K E, Fischer; T, Stargardt: The diffusion of generics after patent expiry in Germany. In: European Journal of Health Economics, Vol 17 (2016) No 8, p. 1027-1040. doi:10.1007/s10198-015-0744-3CitationDetails
• G, Hostenkamp; K E, Fischer; K, Borch-Johnsen: Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. In: Health Policy, Vol 120 (2016) No 12, p. 1404-1411. doi:10.1016/j.healthpol.2016.09.020CitationDetails
• K E, Fischer; T, Heisser; T, Stargardt: Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. In: Health Policy, Vol 120 (2016) No 10, p. 1115-1122. doi:10.1016/j.healthpol.2016.08.001CitationDetails
• D, Guhl; T, Stargardt; U, Schneider; K E, Fischer: Dispensing behaviour of pharmacies in prescription drug markets. In: Health Policy, Vol 120 (2016) No 2, p. 190-197. doi:10.1016/j.healthpol.2016.01.010CitationDetails
• K E, Fischer; R, Leidl: Analysing coverage decision-making: opening Pandora’s box?. In: Eur J Health Econ, Vol 15 (2014) No 9, p. 889-906. doi:10.1007/s10198-014-0566-8CitationDetails
• K E, Fischer; T, Stargardt: Early Benefit Assessment of Pharmaceuticals in Germany Manufacturers’ Expectations versus the Federal Joint Committee’s Decisions. In: Med Decis Making, Vol 34 (2014) No 8, p. 1030-1047. doi:10.1177/0272989X14546377CitationDetails
• K E, Fischer; W H, Rogowski: Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe. In: International Journal of Environmental Research and Public Health, Vol 11 (2014) No 5, p. 5403-5430. doi:10.3390/ijerph110505403CitationDetails
• K E, Fischer; W H, Rogowski; R, Leidl; B, Stollenwerk: Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. In: Health Policy, Vol 112 (2013) No 3, p. 187-196. doi:10.1016/j.healthpol.2013.04.011CitationDetails
• K E, Fischer; B, Stollenwerk; W H, Rogowski: Link between Process and Appraisal in Coverage decisions: An Analysis with Structural Equation Modeling. In: Medical Decision Making, Vol 33 (2013) No 8, p. 1009-1025. doi:10.1177/0272989X13490837CitationDetails
• K E, Fischer: A systematic review of coverage decision-making on health technologies—Evidence from the real world. In: Health Policy, Vol 107 (2012) No 2-3, p. 218-230. doi:10.1016/j.healthpol.2012.07.005CitationDetails
• K E, Fischer: Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes. In: BMC Medical Informatics and Decision Making, Vol 12 (2012) No 1, p. 83. doi:10.1186/1472-6947-12-83CitationDetails
• K E, Fischer; S D, Grosse; W H, Rogowski: The role of health technology assessment in coverage decisions on newborn screening. In: International Journal of Technology Assessment in Health Care, Vol 27 (2011) No 04, p. 313-321. doi:10.1017/S0266462311000468CitationDetails
• K E, Fischer; R, Leidl; W H, Rogowski: A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention. In: Health Policy, Vol 101 (2011) No 3, p. 290-299. doi:10.1016/j.healthpol.2011.03.002CitationDetails

Conferences:

Memberships:

• Academy of Management (AOM)
• German Academic Association for Business Research (VHB)
• Verein für Socialpolitik (VfS)
• German Health Economics Association (dggoe)
• International Health Economics Association (iHEA)

Other Duties:

Reviewer activities

Peer-reviewed journals

• Health Economics
• PharmacoEconomics
• Applied Health Economics and Health Policy
• European Journal of Health Economics
• Health Policy
• International Journal of Technology Assessment in Health Care
• BMC Health Services Research
• Applied Economics Quarterly
• B.E. Journal of Economic Analysis and Policy
• BMJ Open
• ClinicoEconomics and Outcomes Research
• Drug Discovery Today
• Expert Reviews on Orphan Drugs
• Health Research Policy and System
• Pharmacotherapy
• Pharmacy Practice
• Perspektiven der Wirtschaftspolitik

Conferences

• World Congress on Health Economics, International Health Economics Association, 2014
• Annual meeting of the German Academic Association for Business Research, 2016
• Academy of Management, 2017, 2018

Voluntary commitments

• Young Lion Health Parliament, first period, organization committee 2012-2014